Table 1.
Baseline patient and transplant characteristics.
| Total, 6995 | No PH, 6966 (99.6) | PH, 29 (0.4) | ||
|---|---|---|---|---|
| Age (mean (SD)) | 9.14 (6.17) | 9.15 (6.17) | 6.90 (6.03) | |
| Age group | <1 year | 665 (9.5) | 659 (9.5) | 6 (20.7) |
| 1–4 years | 1598 (22.8) | 1590 (22.8) | 8 (27.6) | |
| 5–12 years | 2505 (35.8) | 2496 (35.8) | 9 (31.0) | |
| 13–20 years | 2227 (31.8) | 2221 (31.9) | 6 (20.7) | |
| Sex, female | 2893 (41.3) | 2882 (41.3) | 11 (37.9) | |
| Race | White | 5008 (75.8) | 4989 (75.8) | 19 (67.9) |
| American Indian or Alaska Native | 62 (0.9) | 62 (0.9) | 0 (0.0) | |
| Asian | 356 (5.4) | 356 (5.4) | 0 (0.0) | |
| Black or African American | 987 (14.9) | 978 (14.9) | 9 (32.1) | |
| Native Hawaiian or other Pacific Islander | 17 (0.3) | 17 (0.3) | 0 (0.0) | |
| More than one race | 179 (2.7) | 179 (2.7) | 0 (0.0) | |
| Missing | 386 | 385 | 1 | |
| Ethnicity, Hispanic or Latino | 1646 (24.3) | 1640 (24.4) | 6 (20.7) | |
| Missing | 232 | 232 | 0 | |
| Insurance | Private/military/dual insurance | 1801 (59.6) | 1797 (59.6) | 4 (36.4) |
| Public insurance only | 1169 (38.7) | 1162 (38.6) | 7 (63.6) | |
| Uninsured | 54 (1.8) | 54 (1.8) | 0 (0.0) | |
| Missing | 3971 | 3953 | 18 | |
| Neighborhood median household income (median [IQR]) | $52,348 [41,323, 68,774] | $52,348 [41,332, 68,795] | $53,298 [38,198, 62,209] | |
| BMI (median [IQR]) | 18.34 [16.23, 22.06] | 18.34 [16.23, 22.06] | 18.90 [17.56, 24.31] | |
| BMI Classification | Normal | 2159 (58.7) | 2153 (58.8) | 6 (46.2) |
| Overweight | 601 (16.4) | 598 (16.3) | 3 (23.1) | |
| Obese | 643 (17.5) | 639 (17.4) | 4 (30.8) | |
| Underweight | 272 (7.4) | 272 (7.4) | 0 (0.0) | |
| Missing | 3320 | 3304 | 16 | |
| Indication for transplant | Malignant disease | 4013 (57.4) | 3998 (57.4) | 15 (51.7) |
| Non-malignant hematologic disease | 1833 (26.2) | 1827 (26.2) | 6 (20.7) | |
| Metabolic disorders | 324 (4.6) | 320 (4.6) | 4 (13.8) | |
| Primary immunodeficiency | 805 (11.5) | 801 (11.5) | 4 (13.8) | |
| Other disease | 20 (0.3) | 20 (0.3) | 0 (0.0) | |
| HCT comorbidity index | 0 | 4638 (66.8) | 4623 (66.8) | 15 (51.7) |
| 1 | 910 (13.1) | 910 (13.2) | 0 (0.0) | |
| 2 | 384 (5.5) | 382 (5.5) | 2 (6.9) | |
| 3+ | 1016 (14.6) | 1004 (14.5) | 12 (41.4) | |
| Missing | 47 | 47 | 0 | |
| Karnofsky score | 100 | 3714 (54.1) | 3700 (54.2) | 14 (48.3) |
| 90 | 2164 (31.5) | 2159 (31.6) | 5 (17.2) | |
| <=80 | 982 (14.3) | 972 (14.2) | 10 (34.5) | |
| Missing | 135 | 135 | 0 | |
| Conditioning regimen | RIC/NMA | 1793 (25.8) | 1788 (25.8) | 5 (17.2) |
| MAC-No TBI | 2675 (38.4) | 2662 (38.4) | 13 (44.8) | |
| MAC-TBI | 2436 (35.0) | 2425 (35.0) | 11 (37.9) | |
| No conditioning | 57 (0.8) | 57 (0.8) | 0 (0.0) | |
| Missing | 34 | 34 | 0 | |
| ATG/Alemtuzumab conditioning | Neither | 2770 (50.5) | 2760 (50.5) | 10 (45.5) |
| ATG alone | 2706 (49.3) | 2694 (49.3) | 12 (54.5) | |
| Alemtuzumab alone | 12 (0.2) | 12 (0.2) | 0 (0.0) | |
| Missing | 1507 | 1500 | 7 | |
| Graft type | Bone marrow | 4022 (57.5) | 4009 (57.6) | 13 (44.8) |
| Cord blood | 1911 (27.3) | 1898 (27.2) | 13 (44.8) | |
| Peripheral blood | 1062 (15.2) | 1059 (15.2) | 3 (10.3) | |
| HLA matching | HLA-identical sibling | 1860 (26.6) | 1857 (26.7) | 3 (10.3) |
| Well-matched unrelated (8/8) | 1888 (27.0) | 1885 (27.1) | 3 (10.3) | |
| Partially matched related | 429 (6.1) | 426 (6.1) | 3 (10.3) | |
| Partially matched unrelated | 830 (11.9) | 823 (11.8) | 7 (24.1) | |
| Cord blood | 1911 (27.3) | 1898 (27.3) | 13 (44.8) | |
| Missing | 77 | 77 | 0 | |
| Sex matching | Matched | 2762 (39.5) | 2756 (39.6) | 6 (20.7) |
| Mismatch | 2311 (33.1) | 2301 (33.1) | 10 (34.5) | |
| Cord blood | 1911 (27.4) | 1898 (27.3) | 13 (44.8) | |
| Missing | 11 | 11 | 0 | |
| Recipient CMV status, positive | 3872 (56.3) | 3852 (56.2) | 20 (71.4) | |
| Missing | 116 | 115 | 1 | |
| GVH prophylaxis regimen | CNI + MTX | 3316 (47.4) | 3308 (47.5) | 8 (27.6) |
| CNI + MMF | 2117 (30.3) | 2103 (30.2) | 14 (48.3) | |
| CNI +/- others | 1049 (15.0) | 1044 (15.0) | 5 (17.2) | |
| TCD | 349 (5.0) | 347 (5.0) | 2 (6.9) | |
| Other/missing | 164 (2.4) | 164 (2.4) | 0 (0.0) | |
| Acute GVHD (max grade) | None | 3629 (51.9) | 3609 (51.8) | 20 (69.0) |
| Grade I | 926 (13.2) | 923 (13.3) | 3 (10.3) | |
| Grade II | 1170 (16.7) | 1167 (16.8) | 3 (10.3) | |
| Grade III | 673 (9.6) | 671 (9.6) | 2 (6.9) | |
| Grade IV | 373 (5.3) | 373 (5.4) | 0 (0.0) | |
| Present, grade unknown | 214 (3.1) | 214 (3.1) | 0 (0.0) | |
| Missing | 10 | 9 | 1 | |
| Chronic GVHD (max grade) | None | 5035 (72.0) | 5010 (71.9) | 25 (86.2) |
| Limited | 759 (10.9) | 757 (10.9) | 2 (6.9) | |
| Extensive | 1180 (16.9) | 1178 (16.9) | 2 (6.9) | |
| Present, grade unknown | 2 (0.0) | 0 (0.0) | 0 (0.0) | |
| Missing | 19 | 19 | 0 | |
Values represent n (%) unless otherwise indicated. RIC (Reduced Intensity Chemotherapy). NMA (Non-Myeloablative). TBI (Total Body Irradiation). ATG (Anti-Thymocyte Globulin). HLA (Human Leukocyte Antigen). CNI (Calcineurin Inhibitor). MTX (Methotrexate). MMF (Mycophenolate Mofetil). TCD (T Cell Depletion). GVHD (Graft Versus Host Disease).